chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 73.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Headache, Palpitations, Paraesthesia, Tinnitus
Clinical narrative: Headache; ringing in both ears; racing heart; tingling both hands; This is a spontaneous report from a contactable consumer, the patient. A 73-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 25Mar2021 at 10:00 (at the age of 73-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6201) via an unspecified route of administration in the left arm on 04Mar2021 at 10:00 (at the age of 73-year-old) as a single dose for COVID-19 immunisation. On 26Mar2021 at 03:00, the patient experienced headache, ringing in both ears, racing heart, and tingling in both hands. These events resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken as a result of these events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, ringing in both ears, racing heart, and tingling in both hands were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 46.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pyrexia, Vaccination site pruritus
Clinical narrative: High grade fever (102 F); Frontal headache; Reddish-pink wheal at injection site 1 in x 0.8 in; Itchiness at injection site (left arm); This is a spontaneous report from a contactable consumer, the patient. A 46-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 21Apr2021 at 18:00 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. Medical history included childhood asthma. The patient was allergic to dust and tree pollen. Concomitant medications included loratadine (CLARITIN). The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 31Mar2021 at 18:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021 at 03:00, 9 hours after the vaccination, the patient experienced itchiness at injection site in the left arm; at 07:00, 13 hours post vaccination, the patient had reddish-pink wheal at injection site 1 inch x 0.8 inch; at 14:00, 20 hours post vaccination, the patient experienced high grade fever and frontal headache. On 22Apr2021 at 14:00, the patient underwent body temperature test and the result was 102 Fahrenheit (F). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events which included treatment with Tylenol 500 mg as necessary (prn) and water therapy. The clinical outcome of the events itchiness at injection site (left arm), reddish-pink wheal at injection site 1 inch x 0.8 inch, high grade fever (102 F) and frontal headache were not resolved.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 46.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Body temperature, Headache, Pyrexia, Vaccination site erythema, Vaccination site pruritus
Clinical narrative: High grade fever (102 F); Frontal headache; Reddish-pink wheal at injection site 1 in x 0.8 in; Itchiness at injection site (left arm); This is a spontaneous report from a contactable consumer, the patient. A 46-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 21Apr2021 at 18:00 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. Medical history included childhood asthma. The patient was allergic to dust and tree pollen. Concomitant medications included loratadine (CLARITIN). The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 31Mar2021 at 18:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021 at 03:00, 9 hours after the vaccination, the patient experienced itchiness at injection site in the left arm; at 07:00, 13 hours post vaccination, the patient had reddish-pink wheal at injection site 1 inch x 0.8 inch; at 14:00, 20 hours post vaccination, the patient experienced high grade fever and frontal headache. On 22Apr2021 at 14:00, the patient underwent body temperature test and the result was 102 Fahrenheit (F). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events which included treatment with Tylenol 500 mg as necessary (prn) and water therapy. The clinical outcome of the events itchiness at injection site (left arm), reddish-pink wheal at injection site 1 inch x 0.8 inch, high grade fever (102 F) and frontal headache were not resolved.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 60.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Erythema, Myalgia, Peripheral swelling, Swelling face
Clinical narrative: Mild swelling of face; Muscle pain across shoulder and arms; Joint pain: Shoulder, elbow, finger, knees, and toes; Mild swelling and redness of hands; Mild swelling and redness of hands; Numbness in hands; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0176) via an unspecified route of administration in the left arm on 07May2021 at 10:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to all fruit and nuts. Concomitant medications included diphenhydramine hydrochloride (BENADRYL) as needed. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 07May2021 at 10:30, within 30 minutes of vaccination, the patient experienced muscle pain across shoulder and arms, joint pain: shoulder, elbow, finger, knees, toes, mild swelling, redness of hands and numbness in hands. On 08May2021, the next day, the patient experienced mild swelling of face. The reaction was similar to allergic to fruit (all) and nuts. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the reported events and included treatment with BENADRYL (the patient took as if an allergic reaction- as reported). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events muscle pain across shoulder and arms, joint pain: shoulder, elbow, finger, knees and toes, mild swelling and redness of hands, numbness in hands and mild swelling of face were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Erythema, Hypoaesthesia, Myalgia, Peripheral swelling
Clinical narrative: Mild swelling of face; Muscle pain across shoulder and arms; Joint pain: Shoulder, elbow, finger, knees, and toes; Mild swelling and redness of hands; Mild swelling and redness of hands; Numbness in hands; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0176) via an unspecified route of administration in the left arm on 07May2021 at 10:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to all fruit and nuts. Concomitant medications included diphenhydramine hydrochloride (BENADRYL) as needed. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 07May2021 at 10:30, within 30 minutes of vaccination, the patient experienced muscle pain across shoulder and arms, joint pain: shoulder, elbow, finger, knees, toes, mild swelling, redness of hands and numbness in hands. On 08May2021, the next day, the patient experienced mild swelling of face. The reaction was similar to allergic to fruit (all) and nuts. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the reported events and included treatment with BENADRYL (the patient took as if an allergic reaction- as reported). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events muscle pain across shoulder and arms, joint pain: shoulder, elbow, finger, knees and toes, mild swelling and redness of hands, numbness in hands and mild swelling of face were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Swelling face
Clinical narrative: Mild swelling of face; Muscle pain across shoulder and arms; Joint pain: Shoulder, elbow, finger, knees, and toes; Mild swelling and redness of hands; Mild swelling and redness of hands; Numbness in hands; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0176) via an unspecified route of administration in the left arm on 07May2021 at 10:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to all fruit and nuts. Concomitant medications included diphenhydramine hydrochloride (BENADRYL) as needed. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 07May2021 at 10:30, within 30 minutes of vaccination, the patient experienced muscle pain across shoulder and arms, joint pain: shoulder, elbow, finger, knees, toes, mild swelling, redness of hands and numbness in hands. On 08May2021, the next day, the patient experienced mild swelling of face. The reaction was similar to allergic to fruit (all) and nuts. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the reported events and included treatment with BENADRYL (the patient took as if an allergic reaction- as reported). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events muscle pain across shoulder and arms, joint pain: shoulder, elbow, finger, knees and toes, mild swelling and redness of hands, numbness in hands and mild swelling of face were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Chills, Dizziness, Myalgia, Pyrexia
Clinical narrative: Dizzy spells day of,; Fever; Muscle aches; Chills; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 10May2021 at 13:15 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient did not have allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not take concomitant medications within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 19Apr2021 at 13:15 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. On 10May2021 at 16:15, the patient experienced dizzy spells day of, fever and muscle aches, chills the following day. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events dizzy spells day of, fever and muscle aches, chills were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Rash
Clinical narrative: Body rash located mainly on left side of body; on left side of neck, left arm, left side of stomach, left calf, left and right foot, left and right ankle also on right arm, right foot, right ankle, right calf; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8733) via an unspecified route of administration in the left arm on 24Apr2021 at 13:00 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included herpes simplex type 1 (HSV1). The patient had no known allergies to medications, food, or other products. The patient did not receive any concomitant medications. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03May2021 at 16:30, the patient experienced body rash located mainly on left side of body. The body rash was located on left side of neck, left arm, left side of stomach, left calf, left and right foot, left and right ankle also on right arm, right foot, right ankle, and right calf. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measure was taken as a result of the event and included treatment with triamcinolone acetonide cream USP 0.1%. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event body rash located mainly on left side of body; on left side of neck, left arm, left side of stomach, left calf, left and right foot, left and right ankle also on right arm, right foot, right ankle, right calf was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 18.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chest discomfort, Chills, Headache, Hyperhidrosis, Nausea
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 18-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the left arm on 10May2021 at 13:45 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included antibiotic minocycline hydrochloride (MINOCIN) and vitamin d nos (MANUFACTURER UNKNOWN) supplements, both from an unknown dates for unknown indications and unknown if ongoing. The patient previously received morphine sulfate (MANUFACTURER UNKNOWN) for an unknown indication on an unknown date and experienced drug allergy and received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 19Apr2021 at 13:30 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. On 11May2021 at 04:30, the patient experienced chills, sweating throughout the day, headache, full body ache, trouble sleeping, tightness in the chest, tiredness, and queasy stomach. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, sweating throughout the day, headache, full body ache, trouble sleeping, tightness in the chest, tiredness, and queasy stomach was unknown at time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 18.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pain
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 18-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the left arm on 10May2021 at 13:45 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included antibiotic minocycline hydrochloride (MINOCIN) and vitamin d nos (MANUFACTURER UNKNOWN) supplements, both from an unknown dates for unknown indications and unknown if ongoing. The patient previously received morphine sulfate (MANUFACTURER UNKNOWN) for an unknown indication on an unknown date and experienced drug allergy and received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 19Apr2021 at 13:30 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. On 11May2021 at 04:30, the patient experienced chills, sweating throughout the day, headache, full body ache, trouble sleeping, tightness in the chest, tiredness, and queasy stomach. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, sweating throughout the day, headache, full body ache, trouble sleeping, tightness in the chest, tiredness, and queasy stomach was unknown at time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 18.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abdominal discomfort, Chest discomfort, Chills, Fatigue, Headache
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 18-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the left arm on 10May2021 at 13:45 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included antibiotic minocycline hydrochloride (MINOCIN) and vitamin d nos (MANUFACTURER UNKNOWN) supplements, both from an unknown dates for unknown indications and unknown if ongoing. The patient previously received morphine sulfate (MANUFACTURER UNKNOWN) for an unknown indication on an unknown date and experienced drug allergy and received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 19Apr2021 at 13:30 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. On 11May2021 at 04:30, the patient experienced chills, sweating throughout the day, headache, full body ache, trouble sleeping, tightness in the chest, tiredness, and queasy stomach. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, sweating throughout the day, headache, full body ache, trouble sleeping, tightness in the chest, tiredness, and queasy stomach was unknown at time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 18.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hyperhidrosis, Initial insomnia, Pain
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 18-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the left arm on 10May2021 at 13:45 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included antibiotic minocycline hydrochloride (MINOCIN) and vitamin d nos (MANUFACTURER UNKNOWN) supplements, both from an unknown dates for unknown indications and unknown if ongoing. The patient previously received morphine sulfate (MANUFACTURER UNKNOWN) for an unknown indication on an unknown date and experienced drug allergy and received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 19Apr2021 at 13:30 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. On 11May2021 at 04:30, the patient experienced chills, sweating throughout the day, headache, full body ache, trouble sleeping, tightness in the chest, tiredness, and queasy stomach. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, sweating throughout the day, headache, full body ache, trouble sleeping, tightness in the chest, tiredness, and queasy stomach was unknown at time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Headache, Pyrexia, SARS-CoV-2 test negative
Clinical narrative: Low-grade fever; Intermittent headache; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EW0176) via an unspecified route of administration in the left arm on 25Apr2021 at 01:15 (at the age of 23-year-old) as a single dose for COVID-19 immunisation. Medical history included crohn's disease and penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medication within two weeks of vaccination. On 26Apr2021 at 13:15, the patient experienced low-grade fever and intermittent headache, which were continued for around two weeks. The events resulted in doctor or other healthcare professional office/clinic visit. On 30Apr2021, the patient underwent lab test which included rapid test for COVID-19 and the result was negative. On 05May2021, the patient underwent lab test which included PCR test for COVID-19 and the result was negative. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events low-grade fever and Intermittent headache was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Headache, Pyrexia, SARS-CoV-2 test
Clinical narrative: Low-grade fever; Intermittent headache; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EW0176) via an unspecified route of administration in the left arm on 25Apr2021 at 01:15 (at the age of 23-year-old) as a single dose for COVID-19 immunisation. Medical history included crohn's disease and penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medication within two weeks of vaccination. On 26Apr2021 at 13:15, the patient experienced low-grade fever and intermittent headache, which were continued for around two weeks. The events resulted in doctor or other healthcare professional office/clinic visit. On 30Apr2021, the patient underwent lab test which included rapid test for COVID-19 and the result was negative. On 05May2021, the patient underwent lab test which included PCR test for COVID-19 and the result was negative. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events low-grade fever and Intermittent headache was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Muscle spasms, Muscular weakness, Pain, Tremor
Clinical narrative: Occurring approx. daily in Right Arm: Muscle spasms; Occurring approx. daily in Right Arm: shooting pain down arm; Occurring approx. daily in Right Arm: shooting pain into wrist (painful enough to make stop what doing); Muscle weakness; shaking arm & hand, unable to make fist; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the right arm on 25Mar2021 at 16:00 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Medical history included chronic migraines. The patient had known allergy to peaches, nectarines and grasses. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included erenumab aooe (AIMOVIG) and trazodone (MANUFACTURER UNKNOWN) both for unknown indications from an unknown start date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the right arm on 04Mar2021 at 16:00 (at the age of 41-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 27Mar2021 at 14:00, the patient experienced muscle spasms, shooting pain down arm and into wrist which was painful enough to make her stop what she was doing, shaking arm and hand, unable to make fist and also muscle weakness. These occurred daily in right arm. On 30Apr2021, the patient underwent lab tests and procedures, which included COVID-19 test (nasal swab) and the result was negative. Since the vaccination, the patient had been tested for COVID-19. The events did not result in doctors or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of events. The clinical outcome of the events, muscle spasms, shooting pain down arm and into wrist and muscle weakness was not recovered at the time of report.  No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Muscle spasms, Muscular weakness, Pain, SARS-CoV-2 test
Clinical narrative: Occurring approx. daily in Right Arm: Muscle spasms; Occurring approx. daily in Right Arm: shooting pain down arm; Occurring approx. daily in Right Arm: shooting pain into wrist (painful enough to make stop what doing); Muscle weakness; shaking arm & hand, unable to make fist; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the right arm on 25Mar2021 at 16:00 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Medical history included chronic migraines. The patient had known allergy to peaches, nectarines and grasses. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included erenumab aooe (AIMOVIG) and trazodone (MANUFACTURER UNKNOWN) both for unknown indications from an unknown start date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the right arm on 04Mar2021 at 16:00 (at the age of 41-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 27Mar2021 at 14:00, the patient experienced muscle spasms, shooting pain down arm and into wrist which was painful enough to make her stop what she was doing, shaking arm and hand, unable to make fist and also muscle weakness. These occurred daily in right arm. On 30Apr2021, the patient underwent lab tests and procedures, which included COVID-19 test (nasal swab) and the result was negative. Since the vaccination, the patient had been tested for COVID-19. The events did not result in doctors or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of events. The clinical outcome of the events, muscle spasms, shooting pain down arm and into wrist and muscle weakness was not recovered at the time of report.  No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Tremor
Clinical narrative: Occurring approx. daily in Right Arm: Muscle spasms; Occurring approx. daily in Right Arm: shooting pain down arm; Occurring approx. daily in Right Arm: shooting pain into wrist (painful enough to make stop what doing); Muscle weakness; shaking arm & hand, unable to make fist; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the right arm on 25Mar2021 at 16:00 (at the age of 52-year-old) as a single dose for COVID-19 immunisation. Medical history included chronic migraines. The patient had known allergy to peaches, nectarines and grasses. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included erenumab aooe (AIMOVIG) and trazodone (MANUFACTURER UNKNOWN) both for unknown indications from an unknown start date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the right arm on 04Mar2021 at 16:00 (at the age of 41-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 27Mar2021 at 14:00, the patient experienced muscle spasms, shooting pain down arm and into wrist which was painful enough to make her stop what she was doing, shaking arm and hand, unable to make fist and also muscle weakness. These occurred daily in right arm. On 30Apr2021, the patient underwent lab tests and procedures, which included COVID-19 test (nasal swab) and the result was negative. Since the vaccination, the patient had been tested for COVID-19. The events did not result in doctors or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of events. The clinical outcome of the events, muscle spasms, shooting pain down arm and into wrist and muscle weakness was not recovered at the time of report.  No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Back pain, Hypoaesthesia, Pain in extremity, Paraesthesia, Sensory disturbance
Clinical narrative: next day tingling in hands; Numbness in left side of body, primarily left face, head and sometimes in neck and shoulder/ numbness in waves through body; Episodes of tingling; Some pain in right leg but only periodic. Some periodic pain in finger tips and toes; Night of vaccine developed lower back pain/ days of lower back pain has persisted since then; tingling in feet; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 15Apr2021 at 15:45 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. Medical history included minor chronic irritable bowel syndrome (IBSD) with lactose, all blood tests fine except minor low tri-iodothyronine (T3) level in past, lactose intolerance, latex allergy and nickel sensitivity. Prior to the vaccination, the patient was not diagnosed with COVID-19. On an unknown date in the past, the patient underwent lab tests and investigations that included blood tests and the result was reported as all blood tests fine except minor low T3 level. Concomitant medications included colecalciferol (VITAMIN D3), iodine (MANUFACTURER UNKNOWN), zinc (MANUFACTURER UNKNOWN), k2 (MANUFACTURER UNKNOWN) and electrolytes (manufacturer: ULTIMA), all for unknown indications from unknown dates and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15Apr2021 at 21:00, night of vaccination, the patient experienced lower back pain and tingling in feet. On 16Apr2021, next day, patient experienced tingling in hands, numbness in left side of body, primarily left face, head and sometimes in neck and shoulder. Episodes of tingling, numbness in waves through body, days of lower back pain had persisted since then. Some pain in right leg but was only periodic and some periodic pain in finger tips and toes. The events resulted in doctor or other health care professional office/clinic visit. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events lower back pain, tingling in feet, tingling in hands, numbness in left side of body, primarily left face, head and sometimes in neck and shoulder, episodes of tingling, numbness in waves through body, pain in right leg that was only periodic and periodic pain in finger tips and toes were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Back pain, Blood test, Hypoaesthesia, Pain in extremity, Paraesthesia
Clinical narrative: next day tingling in hands; Numbness in left side of body, primarily left face, head and sometimes in neck and shoulder/ numbness in waves through body; Episodes of tingling; Some pain in right leg but only periodic. Some periodic pain in finger tips and toes; Night of vaccine developed lower back pain/ days of lower back pain has persisted since then; tingling in feet; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 15Apr2021 at 15:45 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. Medical history included minor chronic irritable bowel syndrome (IBSD) with lactose, all blood tests fine except minor low tri-iodothyronine (T3) level in past, lactose intolerance, latex allergy and nickel sensitivity. Prior to the vaccination, the patient was not diagnosed with COVID-19. On an unknown date in the past, the patient underwent lab tests and investigations that included blood tests and the result was reported as all blood tests fine except minor low T3 level. Concomitant medications included colecalciferol (VITAMIN D3), iodine (MANUFACTURER UNKNOWN), zinc (MANUFACTURER UNKNOWN), k2 (MANUFACTURER UNKNOWN) and electrolytes (manufacturer: ULTIMA), all for unknown indications from unknown dates and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15Apr2021 at 21:00, night of vaccination, the patient experienced lower back pain and tingling in feet. On 16Apr2021, next day, patient experienced tingling in hands, numbness in left side of body, primarily left face, head and sometimes in neck and shoulder. Episodes of tingling, numbness in waves through body, days of lower back pain had persisted since then. Some pain in right leg but was only periodic and some periodic pain in finger tips and toes. The events resulted in doctor or other health care professional office/clinic visit. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events lower back pain, tingling in feet, tingling in hands, numbness in left side of body, primarily left face, head and sometimes in neck and shoulder, episodes of tingling, numbness in waves through body, pain in right leg that was only periodic and periodic pain in finger tips and toes were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abdominal pain upper, Body temperature, Chest pain, Chills, Diaphragmalgia
Clinical narrative: Elevated heart rate began 2 days post-vaccine and continues into day 3 post-vaccine; This is a spontaneous report from a non-contactable consumer, the patient. A 30-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 10May2021 at 09:00 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies to medications, food or other products. Concomitant medications included drospirenone, ethinylestradiol (LORYNA) for birth control and minerals nos, vitamins nos (ONE A DAY) for unknown indication and: both from unknown date and unknown if ongoing. The patient previously received received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 19Apr2021 at 9:00 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12May2021 at 08:00, 2 days post-vaccine, the patient experienced elevated heart rate began and continues into day 3 post-vaccine. The event resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the event. Since the vaccination, the patient had been tested for COVID-19. On 12May2021, the patient underwent COVID-19 virus test (nasal swab) and the result was Negative. The clinical outcome of the event Elevated heart was not recovered at the time this report.  No follow-up attempts are needed. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Flatulence, Headache, Malaise, Muscle spasms, Myocardial infarction
Clinical narrative: Elevated heart rate began 2 days post-vaccine and continues into day 3 post-vaccine; This is a spontaneous report from a non-contactable consumer, the patient. A 30-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 10May2021 at 09:00 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies to medications, food or other products. Concomitant medications included drospirenone, ethinylestradiol (LORYNA) for birth control and minerals nos, vitamins nos (ONE A DAY) for unknown indication and: both from unknown date and unknown if ongoing. The patient previously received received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 19Apr2021 at 9:00 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12May2021 at 08:00, 2 days post-vaccine, the patient experienced elevated heart rate began and continues into day 3 post-vaccine. The event resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the event. Since the vaccination, the patient had been tested for COVID-19. On 12May2021, the patient underwent COVID-19 virus test (nasal swab) and the result was Negative. The clinical outcome of the event Elevated heart was not recovered at the time this report.  No follow-up attempts are needed. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pain, Pyrexia, Vaccination site pain
Clinical narrative: Elevated heart rate began 2 days post-vaccine and continues into day 3 post-vaccine; This is a spontaneous report from a non-contactable consumer, the patient. A 30-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 10May2021 at 09:00 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies to medications, food or other products. Concomitant medications included drospirenone, ethinylestradiol (LORYNA) for birth control and minerals nos, vitamins nos (ONE A DAY) for unknown indication and: both from unknown date and unknown if ongoing. The patient previously received received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 19Apr2021 at 9:00 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12May2021 at 08:00, 2 days post-vaccine, the patient experienced elevated heart rate began and continues into day 3 post-vaccine. The event resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the event. Since the vaccination, the patient had been tested for COVID-19. On 12May2021, the patient underwent COVID-19 virus test (nasal swab) and the result was Negative. The clinical outcome of the event Elevated heart was not recovered at the time this report.  No follow-up attempts are needed. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Heart rate, Heart rate increased, SARS-CoV-2 test
Clinical narrative: Elevated heart rate began 2 days post-vaccine and continues into day 3 post-vaccine; This is a spontaneous report from a non-contactable consumer, the patient. A 30-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 10May2021 at 09:00 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies to medications, food or other products. Concomitant medications included drospirenone, ethinylestradiol (LORYNA) for birth control and minerals nos, vitamins nos (ONE A DAY) for unknown indication and: both from unknown date and unknown if ongoing. The patient previously received received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 19Apr2021 at 9:00 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12May2021 at 08:00, 2 days post-vaccine, the patient experienced elevated heart rate began and continues into day 3 post-vaccine. The event resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the event. Since the vaccination, the patient had been tested for COVID-19. On 12May2021, the patient underwent COVID-19 virus test (nasal swab) and the result was Negative. The clinical outcome of the event Elevated heart was not recovered at the time this report.  No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Tinnitus
Clinical narrative: Very loud ringing in ears and pain; Very loud ringing in ears and pain; Very loud ringing in ears and pain; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the first dose of BNT162B2 (PFIZER BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the left arm on 11Mar2021 at 19:15 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included minor hearing loss, mild tinnitus, neck and back pain. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included lysine (L-LYSINE), vitamin d (MANUFACTURER UNKNOWN) and ibuprofen (MANUFACTURER UNKNOWN); all for unknown indication from unknown date and unknown if ongoing. On 25Mar2021, the patient experienced very loud ringing in ears and pain. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event very loud ringing in ears and pain was not recovered at the time of this report. The patient also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 02Apr2021 at 12:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation.   No follow-up attempts are needed. No further information is expected.